Cargando…

In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor

PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low density lipoprotein receptor (LDLR) and promotes degradation of the LDLR. Inhibition of PCSK9 either by reducing its expression or by blocking its activity results in the upregulation of the LDLR and subsequently lowers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Dong-Kook, Lee, Hyun-Sook, Lee, Narae, Lee, Chan Joo, Song, Hyun Joo, Yang, Ga Eul, Yoon, Dojun, Park, Sahng Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541654/ https://www.ncbi.nlm.nih.gov/pubmed/26256967 http://dx.doi.org/10.3349/ymj.2015.56.5.1251

Ejemplares similares

Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
por: Li, Hai, et al.
Publicado: (2009)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Surgical outcomes are hampered after endoscopic ultrasonography-guided ethanol lavage and/or Taxol injection in cystic lesions of the pancreas
por: Kim, Seong-Ryong, et al.
Publicado: (2021)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
por: Katsuki, Shunsuke, et al.
Publicado: (2022)

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
por: Seidah, Nabil G., et al.
Publicado: (2012)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding
por: Deng, Shi-jun, et al.
Publicado: (2019)

Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
por: Li, Jiao, et al.
Publicado: (2017)

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
por: Deshycka, Rhogerry, et al.
Publicado: (2021)

Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
por: Petersen-Uribe, Álvaro, et al.
Publicado: (2021)

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
por: Sarkar, Samantha K., et al.
Publicado: (2022)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
por: Park, Sehoon, et al.
Publicado: (2023)

Intraocular Pressure-Lowering Effect of Latanoprost Is Hampered by Defective Cervical Lymphatic Drainage
por: Kim, Young Kook, et al.
Publicado: (2017)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
por: Shirahama, Ryo, et al.
Publicado: (2018)

Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo
por: Gu, Lili, et al.
Publicado: (2017)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
por: Zhang, Liwen, et al.
Publicado: (2012)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
por: Gadkar, K, et al.
Publicado: (2014)

Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
por: Korman, Max, et al.
Publicado: (2018)

Serum sdLDL-C and Cellular SREBP2-dependent Cholesterol Levels; is there a Challenge on Targeting PCSK9?
por: Soltanmohammadi, Elham, et al.
Publicado: (2016)

PCSK9 positively correlates with plasma sdLDL in community-dwelling population but not in diabetic participants after confounder adjustment
por: Liu, Yan, et al.
Publicado: (2019)

Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells
por: Jack, Allicia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_descnbel1dfm09k3bjviks9hal